Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review) (CROSBI ID 176387)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Perletti, G ; Škerk, Višnja ; Magri, V ; Markotić, Alemka ; Mazzoli, S ; Parnham, MJ ; Wagenlehner, FM ; Naber, KG Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review) // Molecular Medicine Reports, 4 (2011), 6; 1035-1044

Podaci o odgovornosti

Perletti, G ; Škerk, Višnja ; Magri, V ; Markotić, Alemka ; Mazzoli, S ; Parnham, MJ ; Wagenlehner, FM ; Naber, KG

engleski

Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)

Chronic bacterial prostatitis (CBP) is a persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapse episodes caused by incomplete eradication of causative pathogens. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve a permanent cure. Although fluoroquinolones are currently recommended as first-choice agents, macrolide antibiotics are emerging as a noteworthy option for the treatment of CBP. Macrolide antibiotics are characterized by an impressive array of distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties. These properties include high intracellular accumulation in phagocytes and at sites of infection, including the prostate ; broad antibiotic but also biofilm-inhibiting properties ; immunomodulating and inflammation-resolving activities. These features offer particular advantages for the treatment of chronic infections of the prostate gland, which are not easily amenable to drug therapy. Macrolides may be exploited to counteract the unsatisfactory rates of clinical symptom improvement and pathogen eradication. The results of a number of clinical trials support this proposal.

prostatitis; macrolides; azithromycin; biofilm; Chlamydia trachomatis; urological infections; sexually-transmitted infections

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

4 (6)

2011.

1035-1044

objavljeno

1791-2997

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost